CR8997A - Produccion de polipeptidos - Google Patents

Produccion de polipeptidos

Info

Publication number
CR8997A
CR8997A CR8997A CR8997A CR8997A CR 8997 A CR8997 A CR 8997A CR 8997 A CR8997 A CR 8997A CR 8997 A CR8997 A CR 8997A CR 8997 A CR8997 A CR 8997A
Authority
CR
Costa Rica
Prior art keywords
accumulated
amino acids
molar ratio
glutamine
asparagine
Prior art date
Application number
CR8997A
Other languages
English (en)
Inventor
Drapeau Denis
Luan Yen-Tuang
R Mercer James
Wang Wenge
Lasko Daniel
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Publication of CR8997A publication Critical patent/CR8997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee un sistema mejorado para la produccion a gran escala de proteinas y a-Beta en cultivo de celulas, en particular, en medios caracterizados por una o mas de las siguientes caracteristicas: 1) una concentracion acumulada de aminoacidos mayor que aproximadamente 70 mM; 2) una relacion molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; 3) una relacion molar de glutamina acumulada a aminoacidos totales acumulados inferior a aproximadamente 0,2; 4) una relacion molar de ion inorganico acumulado a aminoacidos totales acumulados de entre alrededor de 0,4 y 1; o 5) una concentracion combinada de glutamina acumulada y asparagina acumulada de entre aproximadamente 16 y 36 mM.
CR8997A 2004-08-27 2007-03-16 Produccion de polipeptidos CR8997A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60509704P 2004-08-27 2004-08-27
US60507404P 2004-08-27 2004-08-27
US60494104P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
CR8997A true CR8997A (es) 2007-08-28

Family

ID=35482353

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8997A CR8997A (es) 2004-08-27 2007-03-16 Produccion de polipeptidos

Country Status (20)

Country Link
US (1) US7294484B2 (es)
EP (2) EP2357250B1 (es)
JP (1) JP4864892B2 (es)
KR (2) KR20110036780A (es)
CN (2) CN101048511B (es)
AR (2) AR051017A1 (es)
AU (1) AU2005280034B2 (es)
BR (1) BRPI0514703A (es)
CA (1) CA2578141C (es)
CR (1) CR8997A (es)
EC (1) ECSP077353A (es)
EG (1) EG26462A (es)
ES (1) ES2628012T3 (es)
IL (1) IL181589A0 (es)
MX (1) MX2007002380A (es)
NO (1) NO342433B1 (es)
SG (2) SG158092A1 (es)
TW (1) TWI384069B (es)
WO (1) WO2006026445A1 (es)
ZA (1) ZA200702483B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2243827B2 (en) * 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DK1917276T3 (en) * 2005-08-26 2018-05-07 Ares Trading Sa Process for Preparation of Glycosylated Interferon Beta
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
CN101496387B (zh) 2006-03-06 2012-09-05 思科技术公司 用于移动无线网络中的接入认证的系统和方法
KR101495549B1 (ko) * 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
US8192951B2 (en) * 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
CA2668771C (en) * 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
RU2009132986A (ru) * 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP5576115B2 (ja) 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
US8319819B2 (en) 2008-03-26 2012-11-27 Cisco Technology, Inc. Virtual round-table videoconference
EP2310523B1 (en) * 2008-04-17 2015-06-10 Wyeth LLC Methods for enhanced production of bone morphogenetic proteins
MX347112B (es) 2008-09-15 2017-04-12 Genentech Inc Composiciones y metodos para regular osmolaridad celular.
US8694658B2 (en) 2008-09-19 2014-04-08 Cisco Technology, Inc. System and method for enabling communication sessions in a network environment
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP5913130B2 (ja) * 2010-01-13 2016-04-27 エイピーティー セラピューティックス，インク． 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
CA2795461C (en) 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
PT2563904E (pt) * 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CN102382794B (zh) * 2010-09-01 2013-09-18 山东新时代药业有限公司 一种哺乳动物细胞的灌流培养方法
US8599865B2 (en) 2010-10-26 2013-12-03 Cisco Technology, Inc. System and method for provisioning flows in a mobile network environment
US9338394B2 (en) 2010-11-15 2016-05-10 Cisco Technology, Inc. System and method for providing enhanced audio in a video environment
US8730297B2 (en) 2010-11-15 2014-05-20 Cisco Technology, Inc. System and method for providing camera functions in a video environment
US9143725B2 (en) 2010-11-15 2015-09-22 Cisco Technology, Inc. System and method for providing enhanced graphics in a video environment
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
KR101662412B1 (ko) * 2011-07-01 2016-10-04 암젠 인크 포유동물 세포 배양
US8682087B2 (en) 2011-12-19 2014-03-25 Cisco Technology, Inc. System and method for depth-guided image filtering in a video conference environment
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
HK1218297A1 (zh) * 2013-07-06 2017-02-10 Cadila Healthcare Limited 用於生产单克隆抗体的改进方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
WO2015128314A1 (en) 2014-02-27 2015-09-03 F. Hoffmann-La Roche Ag Modulation of cell growth and glycosylation in recombinant glycoprotein production
EP4512889A3 (en) 2014-03-19 2025-05-07 Pfizer Inc. Method of cell culture
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI707949B (zh) * 2014-06-09 2020-10-21 美商健臻公司 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
KR20240055117A (ko) * 2015-05-29 2024-04-26 베링거 인겔하임 인터내셔날 게엠베하 연속식 배양에서의 세포-제어된 관류
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
EP3377613A1 (en) 2015-11-17 2018-09-26 Pfizer Inc Media and fermentation methods for producing polysaccharides in bacterial cell culture
CA3019753C (en) * 2016-04-05 2021-10-26 Pfizer Inc. Cell culture process
ES2724434T3 (es) * 2017-03-09 2019-09-10 Evonik Technochemie Gmbh Medios de cultivo que comprenden dipéptidos de N-acil-X-glutamina
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
US11339197B2 (en) 2017-10-23 2022-05-24 Progen Co., Ltd. Modified EGF protein, production method therefor, and use thereof
KR102190790B1 (ko) * 2018-10-19 2020-12-15 주식회사 프로젠 변형된 egf 단백질의 생산 방법
JP7471220B2 (ja) * 2017-11-30 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 哺乳動物細胞の培養方法
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
RS65472B1 (sr) 2018-07-03 2024-05-31 Bristol Myers Squibb Co Postupak proizvodnje rekombinantnih proteina
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
JP2022513702A (ja) 2018-12-06 2022-02-09 ファイザー・インク 阻害剤産生が低下した細胞およびその使用方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
JP7822149B2 (ja) 2020-10-02 2026-03-02 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
JP2024538673A (ja) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ｐＨモデリング及び制御のシステム及び方法
JP2025507790A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス
WO2023230209A1 (en) 2022-05-25 2023-11-30 Genentech, Inc. Methods for preparing mammalian cells for perfusion cell culture

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DE4313620A1 (de) * 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
ES2312569T3 (es) 2001-04-30 2009-03-01 Eli Lilly And Company Anticuerpos humanizados.
ES2318006T3 (es) 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
WO2002101019A2 (en) * 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429728B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
EG26462A (en) 2013-11-13
BRPI0514703A (pt) 2008-06-24
ZA200702483B (en) 2018-11-28
NO20071572L (no) 2007-05-23
KR20110036780A (ko) 2011-04-08
TWI384069B (zh) 2013-02-01
CN102827905B (zh) 2016-08-31
NO342433B1 (no) 2018-05-22
AU2005280034A1 (en) 2006-03-09
SG190674A1 (en) 2013-06-28
CN101048511A (zh) 2007-10-03
EP2357250A3 (en) 2014-07-02
CA2578141C (en) 2013-01-08
MX2007002380A (es) 2007-06-15
AR086932A2 (es) 2014-01-29
SG158092A1 (en) 2010-01-29
JP2008511329A (ja) 2008-04-17
AR051017A1 (es) 2006-12-13
CA2578141A1 (en) 2006-03-09
EP2357250A2 (en) 2011-08-17
WO2006026445A1 (en) 2006-03-09
JP4864892B2 (ja) 2012-02-01
ECSP077353A (es) 2007-05-30
EP1789571B1 (en) 2017-04-26
AU2005280034B2 (en) 2012-06-21
US20060121568A1 (en) 2006-06-08
CN102827905A (zh) 2012-12-19
EP2357250B1 (en) 2021-10-06
KR20070085220A (ko) 2007-08-27
IL181589A0 (en) 2007-07-04
ES2628012T3 (es) 2017-08-01
CN101048511B (zh) 2012-07-18
KR101158447B1 (ko) 2012-06-20
US7294484B2 (en) 2007-11-13
EP1789571A1 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
CR8998A (es) PRODUCCION DE TNFR-Ig Y FUSION DE PROTEINA
CR8996A (es) PRODUCCION DE a-BETA
AR051017A1 (es) Produccion de polipeptidos
CY1107960T1 (el) Μeθοδος καθαρισμοy της βακτηριακhς κυτταρολυσiνης
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
AR061976A1 (es) Produccion de glicoproteinas
DK1428878T3 (da) Fremgangsmåde til produktion og oprensning af erythropoietin
DE60238802D1 (de) Membranenelektrodenaufbauten für Brennstoffzelle
DK1846974T3 (da) Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
DE602006005509D1 (de) Absaugbares gel zum dekontaminieren von oberflächen und verwendung dafür
DK0474790T3 (da) Medier til cellevækst og fremgangsmåde til fremstilling deraf
ATE336567T1 (de) Zellkulturmedium
CY1107319T1 (el) Μεθοδος για τον καθαρισμο βακτηριακων κυτταρων και κυτταρικων συστατικων
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
CA2543118A1 (en) Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease
DE602005013263D1 (de) Reinigung von glykopeptiden
DE60035515D1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
ATE406461T1 (de) Rna-bioassay
ATE397691T1 (de) Papierherstellung mit modifizierten kieselsolen als mikropartikel
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
ATE540103T1 (de) Verfahren und vorrichtungen zur bearbeitung einzelner biologischer zellen
EA200701000A1 (ru) Культуральная среда для клеток млекопитающих, не содержащая сыворотки
DE69923595D1 (de) Herstellung von proteinen
WO2001051618A3 (en) Purification of microglial cells